Background: PK bioequivalence of BI 695501, a biosimilar candidate, and the adalimumab originator was demonstrated previously (VOLTAIRE ® -PK: Wynne et al., Expert Opin Investig Drugs 2016;25:1361-70) and led to further clinical development. Objectives: To demonstrate clinical equivalence of BI 695501 with the adalimumab originator by comparing efficacy, safety and immunogenicity using a clinical model sensitive to detect potential differences between the two biologics. Methods: In this 58-week, multi-national, multicentre, randomised, double-blind, parallel arm Phase III study (NCT02137226), 645 pts (18-80 years) with moderate to severe active RA on stable treatment with methotrexate were randomised to receive US-licensed SC adalimumab originator or BI 695501 40mg Q2W for 24 weeks. At Wk 24, pts on adalimumab originator were re-randomised to continue the adalimumab originator or switch to BI 695501 until Wk 48. Pts on BI 695501 were dummy re-randomised. Co-primary end points were proportion of pts achieving ACR20 at Wks 12 and 24. Equivalence between BI 695501 and the adalimumab originator was demonstrated if the relevant confidence intervals (CI) for differences in ACR20 response rate at Wks 12 and 24 were within the predefined margins (Wk 12: 90% CI -12%, 15%; Wk 24: 95% CI -15%, 15%). The secondary efficacy end point was change from baseline in DAS28-ESR at Wks 12 and 24. Safety and immunogenicity were exploratory objectives. Wk 48/58 data will be reported later. Results: The co-primary end points of ACR20 response at Wks 12 and 24 were within the pre-defined criteria for equivalence, demonstrating clinical equivalence between BI 695501 and the adalimumab originator (Table 1) . The proportion of pts with treatment-emergent adverse events (TEAE) was similar between the BI 695501 and the adalimumab originator treatment groups (Table 2) .
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Background: PK bioequivalence of BI 695501, a biosimilar candidate, and the adalimumab originator was demonstrated previously (VOLTAIRE ® -PK: Wynne et al., Expert Opin Investig Drugs 2016; 25:1361-70 ) and led to further clinical development. Objectives: To demonstrate clinical equivalence of BI 695501 with the adalimumab originator by comparing efficacy, safety and immunogenicity using a clinical model sensitive to detect potential differences between the two biologics. Methods: In this 58-week, multi-national, multicentre, randomised, double-blind, parallel arm Phase III study (NCT02137226), 645 pts (18-80 years) with moderate to severe active RA on stable treatment with methotrexate were randomised to receive US-licensed SC adalimumab originator or BI 695501 40mg Q2W for 24 weeks. At Wk 24, pts on adalimumab originator were re-randomised to continue the adalimumab originator or switch to BI 695501 until Wk 48. Pts on BI 695501 were dummy re-randomised. Co-primary end points were proportion of pts achieving ACR20 at Wks 12 and 24. Equivalence between BI 695501 and the adalimumab originator was demonstrated if the relevant confidence intervals (CI) for differences in ACR20 response rate at Wks 12 and 24 were within the predefined margins (Wk 12: 90% CI -12%, 15%; Wk 24: 95% CI -15%, 15%). The secondary efficacy end point was change from baseline in DAS28-ESR at Wks 12 and 24. Safety and immunogenicity were exploratory objectives. Wk 48/58 data will be reported later. Results: The co-primary end points of ACR20 response at Wks 12 and 24 were within the pre-defined criteria for equivalence, demonstrating clinical equivalence between BI 695501 and the adalimumab originator ( Table 1) . The proportion of pts with treatment-emergent adverse events (TEAE) was similar between the BI 695501 and the adalimumab originator treatment groups (Table 2) . Background: In Denmark, biological drugs are provided free by the hospitals to the patients via a tax-based system. In 2015 a non-medical switch from originator infliximab to CT-P13 was conducted (1). According to national guidelines in April 2016, a non-medical switch from originator (ETA, Enbrel ® 50 mg/week) to biosimilar etanercept (SB4, Benepali ® ) was dictated when SB4 was marketed, including patients with inflammatory rheumatic diseases treated in routine care. Objectives: To investigate 3 months' disease activity and 5 months' treatment withdrawal in ETA-treated patients (pts) with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthrits (SpA), who were switched to SB4 and monitored prospectively in the DANBIO registry. Methods: Pts with RA/PsA/SpA followed in DANBIO since start of first bDMARD were included. Disease activity at 3 months before switch (pre-switch), at the switch and after 3 months (post-switch) and changes over time ( pre-switch and post-switch) were calculated. Disease flare was defined as DAS28≥1.2 (RA/PsA) or ASDAS≥1.3 (SpA). Factors associated with withdrawal (gender/ age/diagnosis/bDMARD-treatment-no/comedication methotrexate/baseline CRP/ patient's global score) were explored by multivariable Cox regression analysis. Results: In total, 1548 switch pts were identified (891 RA, 335 PsA, 322 SpA). 60% were women, age (median (IQR) 56 (44-65) yrs)). Prior ETA treatment duration was 5.2 (3.2-8.0) yrs. ETA was the first biological treatment in 49%, and the second in 33% of pts. Concomitant MTX was given in 60% (RA)/49% (PsA)/15% (SpA). Median follow-up time was 154 (110-178) days. Disease activity remained largely unchanged 3 months prior to vs. after the switch (Table) . The proportion of patients with disease flare pre-/post switch was 8%/13% (RA), 9%/13% (PsA), 5%/5% (SpA). Overall, 129 pts (9%) stopped SB4 treatment during 5 months' follow-up (Table) . Prior ETA treatment duration in these patients was 4.5 (2.7-7.1) years. Higher patient's global score (HR 1.12/cm, 95% CI (1.05-1.21), p=0.002) and no concomitant methotrexate (HR 2.28 (1.48-3.52), p<0.001) at baseline were associated with withdrawal.
Conclusions:
In 1548 patients with inflammatory rheumatic diseases treated with ETA for >5 years, disease activity was largely unaffected in the majority of patients 3 months after non-medical switch to SB4 and comparable to the fluctuations observed in the 3 months prior to the switch. Several patients (≈9%)
